chidamide, regorafenib, and iparomlimab/tuvonralimab: clinical trials recruiting now

Fewer than 3 recruiting trials found.

1

Recruiting trials

3

Conditions studied

0

US states with sites

1

Countries

Phase breakdown

Phase 2 1

Conditions being studied

Condition	Trials
Advanced Colorectal Cancer in the Third-line Treatment and Beyond	1
Colorectal cancer	1
pMMR/MSS Advanced Colorectal Cancer	1

Recruiting trials involving chidamide, regorafenib, and iparomlimab/tuvonralimab

The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
NCT06930118 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many recruiting trials involve chidamide, regorafenib, and iparomlimab/tuvonralimab?

1 recruiting trial across 3 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.